These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 18264153)

  • 1. [Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2008 Jan; 128(3):294-7. PubMed ID: 18264153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Medical treatment of Alzheimer's disease].
    Johannsen P
    Ugeskr Laeger; 2006 Oct; 168(40):3424-9. PubMed ID: 17032609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
    Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
    Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinesterase inhibitors in the treatment of dementia.
    Ellis JM
    J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
    Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
    Lockhart IA; Mitchell SA; Kelly S
    Dement Geriatr Cogn Disord; 2009; 28(5):389-403. PubMed ID: 19893314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.
    Ritchie CW; Ames D; Clayton T; Lai R
    Am J Geriatr Psychiatry; 2004; 12(4):358-69. PubMed ID: 15249273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acetylcholinesterase inhibitors for dementia--an update].
    Anghelescu I; Heuser I
    MMW Fortschr Med; 2007 May; 149 Suppl 2():76-8. PubMed ID: 17724973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic management of Alzheimer disease.
    Downey D
    J Neurosci Nurs; 2008 Feb; 40(1):55-9. PubMed ID: 18330411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
    Touchon J; Bergman H; Bullock R; Rapatz G; Nagel J; Lane R
    Curr Med Res Opin; 2006 Jan; 22(1):49-59. PubMed ID: 16393430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
    Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and emerging pharmacological treatment options for dementia.
    Ringman JM; Cummings JL
    Behav Neurol; 2006; 17(1):5-16. PubMed ID: 16720956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
    Kaduszkiewicz H; Zimmermann T; Beck-Bornholdt HP; van den Bussche H
    BMJ; 2005 Aug; 331(7512):321-7. PubMed ID: 16081444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.